Capivast Tablets — Capivasertib 200 mg (64 Tabs) Everest

Prescribed by oncologists for the treatment of adult patients with:

• 🔹 Breast Cancer: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations.
• Used in combination with fulvestrant following progression on endocrine-based regimens.

Sales Unit: Bottle containing 64 film-coated tablets (200 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

• Standard Dosage: 400 mg (two 200 mg tablets) taken orally twice daily (approximately 12 hours apart).
• Schedule: Take for 4 consecutive days, followed by 3 days off. This weekly cycle is repeated.
• Administration: Swallow tablets whole with water, with or without food. Do not chew, crush, or split.
• ✋ Missed Dose: If a dose is missed by more than 4 hours, skip it. Take the next dose at the scheduled time.

• ⛔ Pregnancy & Breastfeeding: Contraindicated due to potential fetal harm.
• Severe hypersensitivity to Capivasertib.
• Pediatric patients (under 18 years).
• Severe hepatic impairment requires caution.

Treatment requires monitoring of blood glucose levels and skin condition:

• ⚠️ Hyperglycemia: High blood sugar is common. Regular glucose monitoring is essential.
• 🤢 Gastrointestinal: Diarrhea (very common), nausea, vomiting, stomatitis (mouth sores).
• 🔴 Dermatologic: Rash, cutaneous adverse reactions (requires monitoring).
• 🩸 Labs: Decreased lymphocytes and hemoglobin.